- Published on 02 March 2015
Sonova Holdings AG has announced its intention to acquire Hansaton Akustik GmbH to expand the Company’s multibrand strategy and increase its strategic market reach in Germany.
Subject to regulatory approval, Hansaton will become the fourth hearing instrument brand under the Sonova umbrella, joining Phonak, Unitron and Advanced Bionics. The acquisition of Hansaton, with its 200 employees, centres in Germany, France and the US and a distribution network in more than 70 countries, will ensure that wholesale will become an even stronger key sales channel for Sonova in Germany and across the world.
Lukas Braunscheweiler, CEO of Sonova said, “The addition of Hansaton reflets our commitment to further develop market access. It will create significant value for Sonova and our customers, notably in Germany.”
Sonova are also targeting Germany as the next key retail market, stating that retail is a fundamental part of its strategy in Germany going forward. The Company has purchased Vitakustik GmbH and Fiebing Hörtechnik GmbH immediately giving them 100 retail outlets in Germany. Braunschweiler said of this move, “We are convinced that with the expanding strategy in Germany we will help to positively contribute to the market.”
Sonova are also looking to reduce costs in its Swiss operation. Custom production will be moved to the UK, some assembly will be moved to China, Swiss-based management and employees will see a pay-freeze in 2015 and costs will be reduced from third parties.
A final announcement was the departure of GVP Marketing, Maarten Barmentlo. He will not be replaced on the Management Board. Lukas Braunschweiler said, “The strategic moves will extend our market leadership position and at the same time assure the cost competitiveness of Sonova’s Swiss based operations.”
The standards applied in testing for US authorisation for self-fitting hearing aids may "jeopardise the hearing health of consumers", says the Hearing Industries Association (HIA) in a letter to the issuing body, the Food and Drug Administration (FDA).
Widespread backing in US audiology supports the introduction of the bipartisan, bicameral Medicare Audiologist Access and Services Act of 2019, already before the US House of Representatives and soon to be put to the Senate.
If the mice are right, there is a drug fix for age-related hearing loss just around the next bureaucratic corner: the hormone aldosterone, combined with anti-inflammatory medicine, can rejuvenate hearing, says the team behind the development.
Audiologists from Australia's Royal Brisbane and Women's Hospital (RBWH) have helped update a recently developed app—HEAROES—designed to help new cochlear implant (CI) users adjust to their new sound environment.
The number of US citizens with eustachian tube dysfunction (ETD), barring those with recent colds, was previously estimated at under 1%, but a new study puts the figure at 4.6%, some 11m people. And the researchers say their figure may underestimate the condition's true prevalence.
Phonak, the world’s leading hearing aid provider, has launched Marvel 2.0, "the next generation of Marvel technology developed to give hearing aid wearers even more hearing performance, more connectivity and more choice".[ ... ]